Eupraxia Pharmaceuticals Inc.

📍 Victoria, Canada🗓 Founded 2012👥 25 employees💰 Last funded Dec 2012
Biotechnology🌐 eupraxiapharmaceuticals.com
Website LinkedIn
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia's product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia’s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2012
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Canada
1
Frequently asked questions
Who invested in Eupraxia Pharmaceuticals Inc.?
Eupraxia Pharmaceuticals Inc. has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Eupraxia Pharmaceuticals Inc. last raise funding?
The most recent investment in Eupraxia Pharmaceuticals Inc. recorded on gritt.io was in December 2012.
When was Eupraxia Pharmaceuticals Inc. founded?
Eupraxia Pharmaceuticals Inc. was founded in 2012.
What industry is Eupraxia Pharmaceuticals Inc. in?
Eupraxia Pharmaceuticals Inc. operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Eupraxia Pharmaceuticals Inc. based?
Eupraxia Pharmaceuticals Inc. is headquartered in Victoria, Canada.